+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Avid Technology Inc - Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 25 Pages
  • July 2026
  • GlobalData
  • ID: 1495540
Avid Technology Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - The analyst’s summarization of the company’s business strategy.
  • SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Avid Technology Inc (Avid) is a provider of integrated solutions and software for the creation, management, and distribution of audio and video content. The company's main activities include developing platforms for media production, storage, distribution, and monetization. Its major products and services encompass audio hardware and software, control surfaces, ingest and playout solutions, and storage systems. Avid operates under Avid NEXIS, MediaCentral, Media Composer, Pro Tools, and Sibelius brand names. The company's products and services are utilized by media enterprises, production teams, and creative professionals in industries such as film, television, and music. Avid serves a global customer base with a presence in various geographic locations, including North America, Europe, and Asia. Avid is headquartered in Burlington, Massachusetts, the US.

Reasons to Buy

  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with the analyst’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.

Table of Contents

Section 1 - About the Company
  • Rigel Pharmaceuticals Inc - Key Facts
  • Rigel Pharmaceuticals Inc - Key Employees
  • Rigel Pharmaceuticals Inc - Key Employee Biographies
  • Rigel Pharmaceuticals Inc - Major Products and Services
  • Rigel Pharmaceuticals Inc - History
  • Rigel Pharmaceuticals Inc - Company Statement
  • Rigel Pharmaceuticals Inc - Locations And Subsidiaries
  • Head Office
Section 2 - Company Analysis
  • Company Overview
  • Rigel Pharmaceuticals Inc - Business Description
  • Other Break-up: Contract Revenues from Collaborations
  • Performance
  • Other Break-up: Government contracts
  • Performance
  • Other Break-up: Product Sales
  • Performance
  • R&D Overview
  • Rigel Pharmaceuticals Inc - Corporate Strategy
  • Rigel Pharmaceuticals Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Rigel Pharmaceuticals Inc - Strengths
  • Rigel Pharmaceuticals Inc - Weaknesses
  • Rigel Pharmaceuticals Inc - Opportunities
  • Rigel Pharmaceuticals Inc - Threats
  • Rigel Pharmaceuticals Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Rigel Pharmaceuticals Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Jul 07, 2026: Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • Jul 01, 2026: Rigel Appoints Board Member Alison L. Hannah, M.D. As Chief Medical Officer
  • Feb 24, 2026: Rigel Schedules Conference Call and Webcast to Report Fourth Quarter and Full-Year 2025 Financial Results
  • Feb 03, 2026: Rigel Appoints Michael P. Miller to the Board of Directors
  • Jan 12, 2026: Rigel Pharmaceuticals Provides Business Update and 2026 Financial Outlook
  • Jan 07, 2026: Onco360 Partners With Rigel Pharmaceuticals to Add Three Therapies to Limited Distribution Portfolio
  • Nov 17, 2025: Rigel Publishes Final 5-Year Data on REZLIDHIA in R/R mIDH1 AML Patients
  • Nov 03, 2025: Rigel Announces Oral And Poster Presentations At The 67th American Society Of Hematology Annual Meeting
  • Oct 08, 2025: Rigel Announces Enrollment of First Patient in Dose Expansion Phase of R289 Study for Lower-Risk MDS
  • Jan 13, 2025: Rigel Provides Business Update and 2025 Outlook
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Rigel Pharmaceuticals Inc, Key Facts
  • Rigel Pharmaceuticals Inc, Key Employees
  • Rigel Pharmaceuticals Inc, Key Employee Biographies
  • Rigel Pharmaceuticals Inc, Major Products and Services
  • Rigel Pharmaceuticals Inc, History
  • Rigel Pharmaceuticals Inc, Key Competitors
  • Rigel Pharmaceuticals Inc, Ratios based on current share price
  • Rigel Pharmaceuticals Inc, Annual Ratios
  • Rigel Pharmaceuticals Inc, Interim Ratios
  • Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Rigel Pharmaceuticals Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Rigel Pharmaceuticals Inc, Performance Chart (2021 - 2025)
  • Rigel Pharmaceuticals Inc, Ratio Charts
  • Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026